Platelet Clinical Trials

70 recruitingLast updated: May 21, 2026

There are 70 actively recruiting platelet clinical trials across 29 countries. Studies span Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1. Top locations include Houston, Texas, United States, Beijing, Beijing Municipality, China, Chicago, Illinois, United States. Updated daily from ClinicalTrials.gov.


Platelet Trials at a Glance

70 actively recruiting trials for platelet are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Not Applicable with 23 trials, with the heaviest enrollment activity in Houston, Beijing, and Chicago. Lead sponsors running platelet studies include Anhui Provincial Hospital, Beijing Tiantan Hospital, and Cardiocentro Ticino.

Browse platelet trials by phase

About Platelet Clinical Trials

Looking for clinical trials for Platelet? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Platelet trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Platelet clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 70 trials

Recruiting
Phase 1

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Inherited Bone Marrow Failure SyndromeFamilial Platelet Disorder With Predisposition to Myeloid Malignancies
National Cancer Institute (NCI)75 enrolled1 locationNCT06090669
Recruiting
Phase 3

Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.

Coronary Artery DiseasePercutaneous Coronary InterventionAcute Coronary Syndromes+3 more
Cardiocentro Ticino355 enrolled1 locationNCT07582835
Recruiting

Coagulation Factors Alterations in Patients Undergoing Complex Thoraco-abdominal Aortic Aneurysm Repair

Platelet ActivationThoraco-abdominal Aortic Aneurysm RepairCoagulation Factors Alterations
University of Thessaly58 enrolled2 locationsNCT06432387
Recruiting

Minimally Invasive Coronary Artery Bypass Supported by Cangrelor

Coronary Artery DiseaseAntiplatelet TherapyMinimally Invasive Coronary Revascularization Surgery
Cardiocentro Ticino30 enrolled1 locationNCT07514962
Recruiting
Phase 2

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

Familial Platelet DisorderHematopoietic
M.D. Anderson Cancer Center6 enrolled1 locationNCT06261060
Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Hodgkin LymphomaNon-Hodgkin LymphomaHematologic Malignancies+14 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting

Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions

Von Willebrand DiseasesMajor Constitutional ThrombopathyPatient on Antiplatelet Drugs
Centre Hospitalier Universitaire Dijon200 enrolled2 locationsNCT03773159
Recruiting
Not Applicable

Surgical Treatment of Peri-implantitis With Adjunctive Application of Platelet Rich Fibrin (PRF)

Peri-implantitisPlatelet-rich FibrinBone Resorption
University of Bern40 enrolled1 locationNCT06679283
Recruiting
Not Applicable

Neonatal Platelet Transfusion Threshold Trial

ThrombosisThrombocytopeniaNeonatal+4 more
NICHD Neonatal Research Network2,433 enrolled20 locationsNCT06676904
Recruiting
Phase 3

Canadian Critical Care Comparative Effectiveness Platform

NutritionVasopressorIntensive Care Unit ICU+1 more
Université de Sherbrooke5,500 enrolled8 locationsNCT06605144
Recruiting

The effect of standardised pathway on the diagnosis and management of platelet-related bleeding disorders.

Inherited abnormalities in platelet number or platelet function.
Northern Sydney Local Health District350 enrolled1 locationACTRN12626000342314
Recruiting
Phase 3

Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy

Myocardial Infarction (MI)Cardiovascular EventsPost Polypectomy Bleeding in Antiplatelet Patients
Chinese University of Hong Kong2,514 enrolled1 locationNCT07052799
Recruiting
Phase 4

IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

Coronary Artery DiseaseAntiplatelet Drugs
Shanghai Zhongshan Hospital2,846 enrolled1 locationNCT06451198
Recruiting
Phase 1

Romiplostim N01 for Platelet Recovery After Haploidentical HSCT

Acute Myeloid LeukemiaHSCTMDS (Myelodysplastic Syndrome)+1 more
First Affiliated Hospital of Zhejiang University130 enrolled1 locationNCT07321626
Recruiting
Not Applicable

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

Arterial Occlusive DiseasesCardiovascular DiseasesCoronary Disease+22 more
Fondazione Ricerca e Innovazione Cardiovascolare ETS576 enrolled1 locationNCT06535568
Recruiting
Not Applicable

The Effects of Intra-articular and Peri-articular Platelet-rich Plasma (PRP) Injections ın Chronic Knee Osteoarthritis

gonarthrosisUltrasonographyPlatelet Rich Plasma Injection
Ankara City Hospital Bilkent42 enrolled1 locationNCT07339137
Recruiting

Pathogen-Reduced Platelet Concentrates: Experience in Routine Practice in Germany

Platelet transfusion
Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen850 enrolled1 locationNCT07354672
Recruiting
Not Applicable

PRP Plus Fractional CO₂ Laser for Acne Scars

Post-Acne Atrophic ScarsCarbon Dioxide LasersPlatelet-Rich Plasma
Gujranwala medical college District Headquarters Hospital, Gujranwala70 enrolled1 locationNCT07352215
Recruiting

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

ThrombophiliaThrombosisSickle Cell Disease+10 more
American Thrombosis and Hemostasis Network3,000 enrolled71 locationsNCT04398628
Recruiting
Not Applicable

Platelets Activation in Brain Neoplasms

Brain NeoplasmsGliomaInflammation+1 more
Fondation Ophtalmologique Adolphe de Rothschild50 enrolled1 locationNCT05049148